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To the editor:
We read with interest the recent paper by Polasek et al. on
the evaluation of zolpidem as a mechanism-based inactivator
of human CYP3A in vitro that was accompanied by the
assessment of its metabolic interaction potential with CYP3A
drugs [1]. The article clearly points out the mechanism of
inactivation of human CYP3A in vitro and describes the
implications of this mechanism for the in vivo metabolic
interactions involving CYP3A. Given the prescription rate of
zolpidem, this issue is of vital importance in terms of the
drug’s efficacy and patients’ safety.
However, one issue that was not addressed in the
discussion of this interesting paper is that of the association
between the patient’s sex and the endocrine specificity of
zolpidem—as if zolpidem pharmacokinetics is a gender-
independent factor. Based on current knowledge, the
pharmacokinetics of zolpidem seems to be related to
endocrine factors associated with CYP3A4 metabolism.
As such, low plasma concentrations of free testosterone
may contribute to lower CYP3A activity, with women
achieving up to 50% higher zolpidem plasma levels, while
exposure to testosterone activates the biotransformation via
CYP3A [2]. This effect is conspicuous in the relative higher
incidence of adverse drug reactions with zolpidem in
women [3].
The conclusions of the study reported in the paper are
valid for the model study on male subjects. It would have
been interesting, however, if the discussion were to have
included the exciting element of endocrine-related differ-
ences in zolpidem action.
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